The decrease in GPR52 expression observed in this study after treatment with all doses of reelin and (2 R,6 R)-HNK further supports the role of therapeutically targeting G protein-coupled receptors in MDD and TRD [45]. The gene discussed is GPR52; the disease is major depressive disorder.